SCHEMBL3014079

SCHEMBL3014079

COc1cc(Cc2csc(N3CCN(S(=O)(=O)c4cc(Cl)cc(Cl)c4)CC3)n2)cc(OC)c1OC

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
USP2 O75604 2/20 0.40
MAPT P10636 2/20 0.40
RECQL P46063 1/20 0.40
HSD17B10 Q99714 1/20 0.40
L3MBTL1 Q9Y468 2/20 0.39
GAA P10253 1/20 0.39
MAPK1 P28482 1/20 0.39
KDM4E B2RXH2 1/20 0.39
HTT P42858 1/20 0.39
LMNA P02545 2/20 0.37
GBA1 P04062 1/20 0.37
THRB P10828 1/20 0.37
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
F2RL3 Q96RI0 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3017960 0.92 MAPT (0.45) ALDH1A1SMN1; SMN2USP2MAPTRECQL
SCHEMBL3019397 0.91 USP2 (0.45) ALDH1A1SMN1; SMN2USP2MAPTRECQL
SCHEMBL3013018 0.90 TSHR (0.43) ALDH1A1SMN1; SMN2USP2MAPTRECQL
SCHEMBL3012681 0.89 SMN1; SMN2 (0.46) ALDH1A1SMN1; SMN2USP2MAPTRECQL
SCHEMBL3006007 0.89 MAPT (0.45) ALDH1A1SMN1; SMN2USP2MAPTRECQL
SCHEMBL3015934 0.88 MAPT (0.45) ALDH1A1SMN1; SMN2USP2MAPTRECQL
SCHEMBL3007845 0.88 ALDH1A1 (0.43) ALDH1A1SMN1; SMN2USP2MAPTRECQL
SCHEMBL3008375 0.87 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2USP2MAPTRECQL
SCHEMBL3018982 0.87 TSHR (0.51) ALDH1A1SMN1; SMN2USP2MAPTRECQL
SCHEMBL3018943 0.86 CYP3A4 (0.44) ALDH1A1SMN1; SMN2USP2MAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ALDH1A1 3510/4885SMN1; SMN2 1/4885USP2 1831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.